+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID04523428

Evaluating Venetoclax Plus Acalabrutinib for Relapsed CLL or SLL After First-Line Venetoclax and Anti-CD20 Antibody Treatment

Led by Stichting Hemato-Oncologie voor Volwassenen Nederland · Updated on 2026-09-21

60

Participants Needed

18

Research Sites

208 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness of retreating patients who have chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL with a combination of venetoclax and acalabrutinib after they previously received a fixed-duration venetoclax plus anti-CD20 antibody treatment. This study aims to provide evidence on the benefit of using venetoclax again in relapsed disease, as this approach has not yet been formally proven. The trial is a phase II, multicenter study focused on treatment in adults with relapsed CLL or SLL. Participants will first receive two cycles of acalabrutinib at 100 mg twice daily. Then they will start a ramp-up dosing of venetoclax, followed by a daily dose of 400 mg venetoclax combined with acalabrutinib for 24 cycles. Treatment continues until a total of 26 cycles have been completed or until the disease progresses, whichever happens first. This combination is expected to achieve undetectable minimal residual disease uMRD, potentially allowing for treatment discontinuation. During the study, participants will be closely monitored with bone marrow flow cytometry after 26 cycles to measure uMRD. Researchers will assess treatment response and disease progression throughout the treatment period. Participants must adhere to scheduled visits and protocol requirements, including laboratory tests and evaluations of organ function. The study will continue until 2032, with primary outcome assessment planned at 26 months.

CONDITIONS

Brief Title

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

Research Team

A

A. Kater

H

H. Visser

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here